Adaptive Biotechnologies continued to raise its 2026 outlook for minimal residual disease testing as clinical volumes expanded. The company reported Q2 MRD revenue of $66.2 million, up 33% year over year, and total Q2 revenue of $71.6 million. Adaptive guided 2026 MRD revenue to $268 million to $278 million, reflecting incremental upward revisions from earlier ranges. Execution details emphasized ClonoSEQ test delivery growth, with the company reporting 36,111 tests in Q2—up 43% year over year—and a key shift toward blood-based MRD testing. Management also pointed to community adoption and serial monitoring via OncoEMR, describing increased fulfillment rates for serial monitoring orders. For the MRD category, the update reinforces the operational scalability of targeted sequencing workflows and the market’s willingness to pay for measurable treatment decision support. It also indicates how guideline updates and payer behavior can translate into sustained testing demand rather than one-off adoption.